Please wait a minute...

中国生物工程杂志

China Biotechnology
China Biotechnology  2017, Vol. 37 Issue (9): 118-125    DOI: 10.13523/j.cb.20170916
    
Progress on High Efficient Expression and Application of Lysostaphin
WANG Xi1, CHEN Xi-ming2, PU Tong-liang1
1. School of Life Sciences, Lanzhou University, Lanzhou 730000, China;
2. Northwest Institute of Eco-Environment and Resources, Chinese Academy of Sciences, Lanzhou 730000, China
Download:   PDF(578KB) HTML
Export: BibTeX | EndNote (RIS)      

Abstract  Lysostaphin(Lys) is usually exogenously expressed in varieties of cells or organisms with gene cloning technology. Lys is a Zn2+ metalloenzyme and a glycylglycinen endopeptidase specific to the pentaglycine cross-bridges of peptidoglycan in the cell walls of Staphylococcus aureus, especially, methicillin-resistant S. aureus(MRSA), then showing an unique bacteriolytic activities. As a kind of efficient antibacterial agent, it has enormous application potentialities in the fields of veterinary drugs and clinical applications. It was reviewed the origins and lysing mechanism of the Lys, the varieties of exogenously gene expression systems. And the developmental situation and prospects of Lys applications were also discussed.

Key wordsLysostaphin      Efficient expression      Staphylococcus aureus      Application     
Received: 27 March 2017      Published: 25 September 2017
ZTFLH:  Q814  
Cite this article:

WANG Xi, CHEN Xi-ming, PU Tong-liang. Progress on High Efficient Expression and Application of Lysostaphin. China Biotechnology, 2017, 37(9): 118-125.

URL:

http://manu60.magtech.com.cn/biotech/10.13523/j.cb.20170916     OR     http://manu60.magtech.com.cn/biotech/Y2017/V37/I9/118

[1] Szweda P, SchielmannM, Kotlowski R,et al.Peptidoglycan hydrolases-potential weapons against Staphylococcus aureus. Appl Microbiol Biotechnol, 2012, 96(5):1157-1174.
[2] Wu J A, Kusuma C, Mond J J, et al. Lysostaphin disrupts Staphylococcus aureus and Staphylococcusepidermidis biofilms on artificial surfaces. Antimicrobial Agents and Chemotherapy,2003,47(11):3407-3414.
[3] Schmelcher M, Donovan D M, Loessner M J. Bacteriophage endolysins as novelantimicrobials. Future Microbiol, 2012,7(10):1147-1171.
[4] Michael W C, Kerstin E. Gordon L A. Mechanism and suppression of lysostaphin resistance in oxacillin-resistant Staphylococcus aureus.Antimicrob Agents Chemother, 2001, 45(5):1431-1437.
[5] 王永,刘沐荣,万海同,等.聚乙二醇修饰重组溶葡球菌酶的初步研究.中国生物工程杂志,2013,33(6):12-17. Wang Y, Liu M R,Wan H T, et al.Chemical modification of lysostaphin with activated polyethlene glycol. China Biotechnology, 2013,33(6):12-17.
[6] García-Cano I, Campos-Gómez M, Contreras-Cruz M,et al.Expression, purification, and characterization of a bifunctional 99-kDa peptidoglycan hydrolase from Pediococcus acidilactici ATCC 8042. Appl Microbiol Biotechnol,2015, 99(20):8563-8573.
[7] Schindler C A,Schuhardt V T. Lysostaphin:A new bacteriolytic agent for the staphylococcus. Proc Natl Acad Sci USA, 1964,51(3):414-421.
[8] Freire Bastos M C, Coutinho B G, Coelho M L, et al. Lysostaphin:A staphylococcal bacteriolysin with potential clinical applications. Pharmaceuticals, 2010, 3(4):1139-1161.
[9] 郭广君,吕素芳,王荣富.外源基因表达系统的研究进展.科学技术与工程,2006,6(5):1671-1678. Guo G J,Lu S F,Wang R F. Progress on the expression system of heterologous gene.Science Technology and Engineering, 2006,6(5):1671-1678.
[10] Chan E C. Expression and purification of recombinant lysostaphin in Escherichia coil. Biotechnology Lettters,1996,18(17):833-838.
[11] Szweda P,Gorczyca G, Filipkowski P,et al.Eficient production of Staphylococcus simulans lysostaphin in benchtop bioreactor by recombinant Escherichia coli.Preparative Biochemistry and Biotechnology,2014,44(4):370-381.
[12] Szweda P, Kotłowski R, Kur J. Neweffective sources of the Staphylococcus simulans lysostaphin. Journal of Biotechnology,2005,117(2):203-213.
[13] Zhang B W, Tao S G, Ma H M,et al. Lysis of mastitis pathogens isolated from dairy cow milk samples by purified recombinant lysostaphin.African Journal of Biotechnology,2012,11(20):4649-4659.
[14] Farhangnia L, Ghaznavi-Rad E, Mollaee N, et al. Cloning, expression, and purification of recombinant lysostaphin from Staphylococcus simulans. Jundishapur J Microbiol,2014,7(5):e10009.
[15] Morello E,Bermúdez-Humarán L G, Llull D, et al.Lactococcus lactis, an efficient cell factory for recombinant protein productionand secretion. Journal of Molecular Microbiology Biotechnology,2008,14(1-3):48-58.
[16] Mierau I, Leij P, Swam I V, et al.Industrial-scale production and purification of a heterologous protein in Lactococcus lactis using the nisin-controlled gene expression system NICE:The case of lysostaphin.Microbial Cell Factories,2005, 4(1):1-9.
[17] Mierau I, Olieman K, Mond J, et al.Optimization of the Lactococcus lactis nisin-controlled gene expression system NICE for industrial applications. Microbial Cell Factories,2005, 4(1):1-12.
[18] Müller D, Bayer K, Mattanovich D. Potentials and limitations of prokaryotic and eukaryotic expression systems for recombinant protein production-a comparative view. Microbial Cell Factories,2006, 61(1):260-262.
[19] 刘晓明,姜宁,张爱忠,等.杂合抗菌肽在毕赤酵母中的表达及其活性测定.中国生物工程杂志,2016,36(2):81-89. Liu X M, Jiang N, Zhang Z A, et al. Expression of hybird antibacterial peptides in Pichia yeast and identification of its biological activity. China Biotechnology, 2016,36(2):81-89.
[20] 傅小蒙,孔令聪,裴志,等.毕赤酵母表达系统优化策略概述.中国生物工程杂志,2015,35(10):86-90. Fu X M,Kong L C,Pei Z, et al. Advance in the research of antimicrobial peptides gene expression in Pichia pastor. China Biotechnology, 2015,35(10):86-90.
[21] Zhao H L, Blazanovic K, Choi Y, et al. Gene and protein sequence optimization for high-level production of fully active and aglycosylated lysostaphin in Pichia pastoris. Applied and Environmental Microbiology, 2014, 80(9):2746-2753.
[22] Schotte P, Dewerte I, Groeve M D, et al. Pichia pastoris MutS strains are prone to misincorporation of O-methyl-l-homoserine at methionine residues when methanol is used as the sole carbon source. Microbial Cell Factories, 2016,15(1):1-9.
[23] Fan W, Plaut K, Bramley A J, et al. Persistency of adenoviral-mediated lysostaphin expression in goat mammary glands. American Dairy Science Association, 2004, 87(3):602-608.
[24] Huang C Y, Hsu J T,Chung P H, et al. Site-specific N-glycosylation of caprine lysostaphin restricts its bacteriolytic activity toward Staphylococcus aureus. Animal Biotechnology, 2013,24(2):129-147.
[25] Klein M, Krönke M, Krut O. Expression of lysostaphin in HeLa cells protects from host cell killing by intracellular Staphylococcus aureus. Medical Microbiology and Immunology,2006,195(3):159-163.
[26] Kerr D E, Plaut K, Bramley A J, et al. Lysostaphin expression in mammary glands confers protection against staphylococcal infection in transgenic mice. Nature Biotechnology,2001,19(1):66-70.
[27] Wall R J, Powell A M, Paape M J, et al. Genetically enhanced cows resist intramammary Staphylococcus aureus infection.Nature Biotechnology,2005,23(4):445-451.
[28] 利凯,马利芹,徐彤,等.重组溶葡萄球菌酶对金葡菌诱导实验性小鼠乳腺炎的防治研究//京津冀畜牧兽医科技创新交流会暨新思想、新观点、新方法论坛论文集, 京津冀畜牧兽医科技创新交流会暨新思想、新观点、新方法论坛,保定,2008, 北京:中国畜牧兽医学会,2008:2519-2522. Li K,Ma L Q,Xu T, et al. The Study of Recombinant Lysostaphin on the Prevention and Treatment of Experimental Mastitis in Mice Induced by Staphylococcus aureus//Proceedings of Beijing, Tianjin and Hebei Animal Husbandry and Veterinary Science and Technology Innovation Exchange Cum Collection of New Ideas, New Ideas, New Methods Forum and Symposium. Proceedings of Beijing, Tianjin and Hebei Animal Husbandry and Veterinary Science and Technology Innovation Exchange Cum Collection of New Ideas, New Ideas, New Methods Forum.Hebei Baoding,2008, Beijing:Chinese Association of Animal Science and Veterinary Medicine,2008:2519-2522.
[29] Schmelcher M, Powell A M, Becker S C, et al. Chimeric phage lysins act synergistically with lysostaphin to kill mastitis-causing staphylococcusaureus in murine mammary glands. Applied and Environmental Microbiology,2012,78(7):2297-2305.
[30] 张继恩,吴聪明,孙永学,等.重组溶葡萄球菌酶对奶牛子宫内膜炎的疗效研究//首届中国兽药大会暨中国畜牧兽医学会动物药品学分会2008年学术年会论文集,首届中国兽药大会暨中国畜牧兽医学会动物药品学分会2008年学术年会,天津,2008,北京:中国畜牧兽医学会,2008:17-23. Zhang J E,Wu C M,Sun Y X, et al.The Study of Recombinant Lysostaphin on Treatment Trial of Endometritis in Dairy Cattle//Proceedings of the First Chinese Veterinary Drug Assembly Animal and Drug Eessays Proceedings of the 2008 Annual Conference of Animal and Veterinary Medicine of China Animal and Veterinary Society, Proceedings of the First Chinese Veterinary Drug Assembly Animal and Drug Eessays Proceedings of the 2008 Annual Conference of Animal and Veterinary Medicine of China Animal and Veterinary Society, Tianjin,2008, Beijing:Chinese Association of Animal Science and Veterinary Medicine,2008,17-23.
[31] 袁怀兵.重组溶葡萄球菌酶对奶牛子宫内膜炎的疗效研究.当代畜禽养殖业,2013,12(19):6-7. Yuan H B. The study of recombinant lysostaphin on treatment trial of endometritis in dairy cattle. Modern Animal Husbandry, 2013,12(19):6-7.
[32] 陆锦春,陈华鹏,马怀彦,等.重组溶葡萄球菌酶在患子宫内膜炎奶牛体内的药代动力学与残留研究.疾病防治,2012,122(2):40-44. Lu J C,Chen H P,Ma H Y, et al. Pharmacokinetics and residue of recombinant lysostaphin in dairy cows with endometritis. Disease Prevention, 2012,122(2):40-44.
[33] 蒋司嘉,张继恩,吴聪明,等.重组溶葡萄球菌酶对奶牛乳房炎的疗效研究.中国兽药杂志,2011,45(12):23-28. Jiang S J,Zhang J E,Wu C M, et al. Therapeutic efficacy of recombinant lysostaphin on bovine mastitis. China Journal of Veterinary Medicine, 2011,45(12):23-28.
[34] 关文怡,李桂伶,郭海龙.重组溶葡萄球菌酶对奶牛隐性乳房炎的治疗试验.山东畜牧兽医,2014,18(9):13-14. Guan W Y,Li J L,Guo H L. Effect of recombinant lysostaphin on subclinical mastitis in dairy cows. Shangdong Journal of Animal Science and Veterinary Medicine, 2014,18(9):13-14.ZK)]
[35] Hoernig K J, Donovan D M, Pithua P, et al. Evaluation of a lysostaphin-fusion protein as a dry-cow therapy for Staphylococcus aureus mastitis in dairy cattle. American Dairy Science Association, 2016, 99(6):4638-4646.
[36] Orlin I, Rokney A, Onn A, et al. Hospital clones of methicillin-resistant Staphylococcus aureus are carried by medical students even before healthcare exposure. Antimicrobial Resistance & Infection Control, 2017, 6(1):15.
[37] 杨雄,刘凤彬,刘洋.溶葡萄球菌酶对控制烧伤创面MRSA感染的临床观察.中国实用医药,2010,5(18):95-96. Yang X,Liu F B,Liu Y.Clinical observation of lysostaphin treatment of burn wounds MRSA infection. China Practical Medicine, 2010,5(18):95-96.
[38] 聂学,李文生,杨文元.复合溶葡萄球菌酶治疗烧伤后期感染创面的疗效观察.中国实用医药,2011,6(3):157-158. Nie X,Li W S,Yang W Y. Curative effect of compound Lysostaphin cures burn wound infection in the late stage. China Practical Medicine, 2011,6(3):157-158.
[39] Quickel J R, Selden R, Caldwell J R, et al. Efficacy and safety of topical lysostaphin treatment of persistent nasal carriage of Staphylococcus aureus. Applied Microbiology, 1971, 22(3):446.
[40] 施强,居丽雯,朱献忠,等.溶葡萄球菌复合酶体外抗流感病毒效果研究.中国卫生检验杂志,2006,16(12):1439-1442. Shi Q,Ju LW,Zhu X Z,et al. Effect of compound lysostaphin on influenza virus in vitro. Chinese Journal of Health Laboratory Technology, 2006,16(12):1439-1442.
[41] Kokaikun J F. Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model. Journal of Antimicrobial Chemotherapy, 2007, 60(5):1051-1059.
[42] Oluola O, Kong L, Fein M, et al. Lysostaphin in treatment of neonatal Staphylococcus aureus infection. Antimicrobial Agents & Chemotherapy, 2007, 51(6):2198-2200.
[43] Desbois A P, Gemmell C G, Coote P J. In vivo efficacy of the antimicrobial peptide ranalexin in combination with the endopeptidase lysostaphin against wound and systemic meticillin-resistant Staphylococcus aureus (MRSA) infections. International Journal of Antimicrobial Agents,2010,35(6):559-565.
[1] JIAO Yang, LIU Heng, Talatibaike·Maimaitijuma, CAO Yong-ping. The Application of Graphene and Derivatives in Orthopedics[J]. China Biotechnology, 2017, 37(8): 78-83.
[2] ZHAO Zhi-guo, CUI Qiang, ZHAO Lin-li, WANG Hai-yan, LI Gang, LIU Lai-jun, AO Wei-hua, MA Cai-xia. Application Progress of the Technology of Droplet Digital PCR[J]. China Biotechnology, 2017, 37(6): 93-96.
[3] WANG Xi, ZHANG Guang-de, CHEN Xi-ming, PU Tong-liang. Heterologous Expression, Mutation, Optimizing the Expression Condition and Characterization of Lysostaphin in Kluyveromyces lactis[J]. China Biotechnology, 2017, 37(12): 49-58.
[4] YAN Peng-cheng, ZHANGY Zhan-jiang, PEI Zhi-yong, FU Yan-ting, CHEN Yu-bao, LIU Tong. Design and Realization of Cloud Platform for Medicinal Plant Conservation[J]. China Biotechnology, 2017, 37(11): 37-44.
[5] WANG Lu-lu, QUAN Chun-shan, XU Yong-bin, CHEN Jin-li, WU Yi, WANG Guan-tian, DONG Yue-sheng. Expression, Purification and Functional Assay of ArlSCA from Staphylococcus aureus[J]. China Biotechnology, 2017, 37(11): 52-58.
[6] LIU Yi-jie, XUE Yong-chang. The Research Progress of Flavonoids in Plants[J]. China Biotechnology, 2016, 36(9): 81-86.
[7] WANG Dian-liang, DU Juan. The Current Research and Development Status of Cell Drug[J]. China Biotechnology, 2016, 36(9): 126-133.
[8] MA Bo-yuan, ZHANG Guang-ming, WANG Hang-yao, XU Hong-zhang, PENG Meng, WANG Yuan-yuan. Research Progress on Application of Photosynthetic Microbial Mixed Culture[J]. China Biotechnology, 2016, 36(8): 113-122.
[9] CHEN Da-Ming, LIU Xiao, MAO Kai-Yun, XIONG Yan. Development Status and Trend Analysis of Synthetic Biology Products[J]. China Biotechnology, 2016, 36(7): 117-126.
[10] WANG Xu-jing, ZHANG Xin, LIU Pei-lei, WANG Zhi-xing. The Application and Safety Assessment of Stacked Transgenic Plant[J]. China Biotechnology, 2016, 36(4): 18-23.
[11] WANG Dian-liang. The Clinical Application of Cell Drug[J]. China Biotechnology, 2016, 36(12): 117-123.
[12] TANG Wen-yan, LUAN Zuo. Biological Characteristics and Clinical Application of Endothelial Progenitor Cells[J]. China Biotechnology, 2016, 36(10): 86-93.
[13] SHEN Liang, TAN Wen-jie. Progress on the Technique and its Application of Reverse Genetics for Coronaviruses[J]. China Biotechnology, 2015, 35(2): 84-91.
[14] WANG Rong-hua, SUN Xiu-juan, LI Qian, YAN Zhen-xin, Peter Proksch. The Research Progress of Marine Functional Molecules Phloroglucinol[J]. China Biotechnology, 2015, 35(10): 115-121.
[15] LIU Lu-gang, JI Xiao-jun, SHEN Meng-qiu, TONG Ying-jia, HUANG He. Red-mediated Scarless Recombination:Strategies and Applications[J]. China Biotechnology, 2014, 34(8): 88-96.